Immunomodulating Drugs for the Treatment of Cancer

Front Cover
Lippincott Williams & Wilkins, Mar 29, 2012 - Medical - 312 pages
Immunomodulating Drugs for the Treatment of Cancer provides a comprehensive resource for clinicians and researchers regarding immunomodulatory (IMiDs) drugs and their rapidly emerging role in cancer medicine. This new class of anticancer agents has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

INTRODUCTION
3
PRECLINICAL DEVELOPMENT
15
CLINICAL DEVELOPMENT
27
Thalidomide for Relapsed or Refractory Myeloma
51
Role of IMiDs as Initial Therapy for Multiple Myeloma
61
Role of Immunomodulatory Drugs for the Treatment of Newly
85
IMiDs As Maintenance Therapy in Multiple Myeloma
107
Lenalidomide for the Treatment of Relapsed or Refractory
121
Thalidomide and Lenalidomide for Treatment
175
Immunomodulatory Drugs for the Treatment of Chronic
191
Lenalidomide for NonHodgkins Lymphoma
217
Clinical Efficacy of Immunomodulatory Drugs in Amyloidosis
231
Immunomodulating Drugs for the Treatment of Prostate Cancer
239
Pomalidomide in Cancer Therapy
253
COMPLICATIONS
269
Toxicity Associated with the Immunomodulating Agents
281

IMiDs and Stem Cell Transplantation in Multiple Myeloma
137
Lenalidomide for the Treatment of Myelodysplastic Syndromes
157

Other editions - View all

Common terms and phrases

Bibliographic information